IN190792B - - Google Patents

Info

Publication number
IN190792B
IN190792B IN2797DE1998A IN190792B IN 190792 B IN190792 B IN 190792B IN 2797DE1998 A IN2797DE1998 A IN 2797DE1998A IN 190792 B IN190792 B IN 190792B
Authority
IN
India
Application number
Other languages
English (en)
Inventor
Nabil Hanna
Gary Ronald Braslawsky
Kandasamy Hariharan
Original Assignee
Idec Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Idec Pharma Corp filed Critical Idec Pharma Corp
Publication of IN190792B publication Critical patent/IN190792B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IN2797DE1998 1997-09-18 1998-09-17 IN190792B (en:Method)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US93335997A 1997-09-18 1997-09-18

Publications (1)

Publication Number Publication Date
IN190792B true IN190792B (en:Method) 2003-08-23

Family

ID=25463798

Family Applications (1)

Application Number Title Priority Date Filing Date
IN2797DE1998 IN190792B (en:Method) 1997-09-18 1998-09-17

Country Status (18)

Country Link
US (4) US20010018054A1 (en:Method)
EP (1) EP1015031A4 (en:Method)
JP (1) JP2001516727A (en:Method)
KR (1) KR100540267B1 (en:Method)
CN (1) CN1234413C (en:Method)
AR (1) AR013012A1 (en:Method)
AU (1) AU742216B2 (en:Method)
CA (1) CA2303178A1 (en:Method)
CO (1) CO4790100A1 (en:Method)
IL (2) IL134937A0 (en:Method)
IN (1) IN190792B (en:Method)
MY (1) MY131805A (en:Method)
NO (1) NO20001413L (en:Method)
RU (1) RU2219947C2 (en:Method)
SA (1) SA98190719B1 (en:Method)
TW (1) TWI252108B (en:Method)
WO (1) WO1999013912A1 (en:Method)
ZA (1) ZA988461B (en:Method)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6197311B1 (en) 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
HK1048772A1 (zh) * 2000-02-28 2003-04-17 Genesegues, Inc. 纳米胶囊包封系统与方法
US7244232B2 (en) * 2001-03-07 2007-07-17 Biomed Solutions, Llc Process for identifying cancerous and/or metastatic cells of a living organism
US20040038303A1 (en) * 2002-04-08 2004-02-26 Unger Gretchen M. Biologic modulations with nanoparticles
MXPA05000403A (es) * 2002-07-15 2005-07-22 Genentech Inc Metodos para identificar tumores que responden al tratamiento con anticuerpos contra erbb2.
US7491395B2 (en) 2002-11-20 2009-02-17 Bestewil Holding B.V. Compositions comprising antigen-complexes, method of making same as well as methods of using the antigen-complexes for vaccination
US7709615B2 (en) 2003-07-15 2010-05-04 Chugai Seiyaku Kabushiki Kaisha Polynucleotides encoding anti-ganglioside antibodies
WO2005012527A1 (en) * 2003-07-21 2005-02-10 Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof
EA012082B1 (ru) 2004-08-03 2009-08-28 Транстек Фарма, Инк. Белки слияния на основе rage и способы их использования
SG161242A1 (en) * 2004-08-03 2010-05-27 Transtech Pharma Inc Rage fusion proteins and methods of use
BRPI0620380B1 (pt) * 2005-12-23 2018-04-24 Gcoder Systems Ab Padrão de posicionamento
WO2007094926A2 (en) * 2006-02-09 2007-08-23 Transtech Pharma, Inc. Rage fusion proteins and methods of use
EA017291B1 (ru) 2006-05-05 2012-11-30 Транстек Фарма, Инк. Белки слияния на основе rage, их композиции и способы их применения
WO2008100470A2 (en) * 2007-02-15 2008-08-21 Transtech Pharma, Inc. Rage - immunoglobulin fusion proteins
WO2009055005A2 (en) * 2007-10-23 2009-04-30 The Regents Of The University Of Colorado Competitive inhibitors of invariant chain expression and/or ectopic clip binding
RU2011142230A (ru) 2009-04-20 2013-05-27 Пфайзер Инк. Контроль гликозилирования белка и композиции и способы, касающиеся этого
MX2012004090A (es) * 2009-10-09 2012-04-20 Sanofi Sa Polipeptidos para unirse al "receptor para productos terminales de glicacion avanzados" asi como composiciones y metodos que involucran los mismos.
AU2011329638C1 (en) * 2010-11-18 2017-04-27 The General Hospital Corporation Novel compositions and uses of anti-hypertension agents for cancer therapy
WO2013078286A1 (en) * 2011-11-22 2013-05-30 Cornell University Methods for stimulating hematopoietic recovery by inhibiting tgf beta signaling
WO2015027082A1 (en) 2013-08-22 2015-02-26 Acceleron Pharma, Inc. Tgf-beta receptor type ii variants and uses thereof
AU2015311857A1 (en) 2014-09-03 2017-03-23 Genesegues, Inc. Therapeutic nanoparticles and related compositions, methods and systems
WO2017024171A1 (en) 2015-08-04 2017-02-09 Acceleron Pharma Inc. Methods for treating myeloproliferative disorders
TW202506185A (zh) 2017-01-20 2025-02-16 法商賽諾菲公司 抗TGF-β抗體及其用途
PT3628049T (pt) 2017-05-04 2023-07-03 Acceleron Pharma Inc Proteínas de fusão do recetor de tgf-beta tipo ii e utilizações dos mesmos
AU2019231205A1 (en) 2018-03-06 2020-09-24 The Trustees Of The University Of Pennsylvania Prostate-specific membrane antigen cars and methods of use thereof
CN114814223A (zh) * 2022-04-20 2022-07-29 昆明市妇幼保健院 一种用于监测及控制疟原虫治疗的系统及设备

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4052A (en) * 1845-05-13 Tktjss
US20020004052A1 (en) * 1990-05-08 2002-01-10 David Berd Composition comprising a tumor cell extract and method of using the composition
MX9204376A (es) * 1991-07-25 1993-02-01 Idec Pharma Corp Composiciones y metodos para inducir respuestas citotoxicas de los linfocitos t.
US6197311B1 (en) * 1991-07-25 2001-03-06 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2146973C (en) 1992-10-29 2008-09-02 Patricia R. Segarini Uses of tgf-.beta. receptor fragment as a therapeutic agent
US5514670A (en) * 1993-08-13 1996-05-07 Pharmos Corporation Submicron emulsions for delivery of peptides
US5932212A (en) * 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents

Also Published As

Publication number Publication date
US6998125B2 (en) 2006-02-14
CN1234413C (zh) 2006-01-04
JP2001516727A (ja) 2001-10-02
US20010019715A1 (en) 2001-09-06
AU742216B2 (en) 2001-12-20
KR100540267B1 (ko) 2006-01-10
IL134937A (en) 2008-04-13
IL134937A0 (en) 2001-05-20
NO20001413D0 (no) 2000-03-17
HK1033653A1 (en) 2001-09-14
CO4790100A1 (es) 1999-05-31
NO20001413L (no) 2000-05-18
WO1999013912A1 (en) 1999-03-25
AR013012A1 (es) 2000-11-22
TWI252108B (en) 2006-04-01
US20010018054A1 (en) 2001-08-30
EP1015031A1 (en) 2000-07-05
CN1279616A (zh) 2001-01-10
MY131805A (en) 2007-09-28
KR20010024109A (ko) 2001-03-26
US20060153848A1 (en) 2006-07-13
US20040137014A1 (en) 2004-07-15
ZA988461B (en) 1999-03-30
RU2219947C2 (ru) 2003-12-27
CA2303178A1 (en) 1999-03-25
SA98190719B1 (ar) 2006-08-06
EP1015031A4 (en) 2004-03-17
AU9565898A (en) 1999-04-05

Similar Documents

Publication Publication Date Title
IN1998CH02232A (en:Method)
IN190792B (en:Method)
IN186867B (en:Method)
ITVE970021A0 (en:Method)
IN189603B (en:Method)
BE2013C047I2 (en:Method)
ITTO970448A0 (en:Method)
ITMI971624A0 (en:Method)
ITMI971158A0 (en:Method)
ITPD970084A0 (en:Method)
ITPD970104A0 (en:Method)
IN188735B (en:Method)
IN187176B (en:Method)
ITPD970144A0 (en:Method)
IN185086B (en:Method)
CN3057730S (en:Method)
CN3056811S (en:Method)
CN3058088S (en:Method)
CN3069727S (en:Method)
CN3058057S (en:Method)
CN3058025S (en:Method)
CN3058000S (en:Method)
CN3057997S (en:Method)
CN3057976S (en:Method)
CN3057977S (en:Method)